Spin-off Reveal Genomics to commercialize a genetic test to customize breast cancer treatment
Reveal Genomics, a spin-off created by the University of Barcelona, Hospital Clínic de Barcelona and the Vall d'Hebron Institute of Oncology, will commercialize HER2DX. This test predicts the prognostic of patients with HER2 positive breast cancer patients (HER2+) in early stages, as well as the probability of patients to respond to given pharmacological treatments before the tumour surgery.
Reveal Genomics, a spin-off created by the University of Barcelona, Hospital Clínic de Barcelona and the Vall d'Hebron Institute of Oncology, will commercialize HER2DX. This test predicts the prognostic of patients with HER2 positive breast cancer patients (HER2+) in early stages, as well as the probability of patients to respond to given pharmacological treatments before the tumour surgery.